Short Interest in Cleveland BioLabs, Inc. (CBLI) Drops By 30.7%
Cleveland BioLabs, Inc. (NASDAQ:CBLI) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 500,700 shares, a decrease of 30.7% from the April 28th total of 722,106 shares. Approximately 13.5% of the shares of the stock are short sold. Based on an average trading volume of 256,101 shares, the days-to-cover ratio is presently 2.0 days.
Shares of Cleveland BioLabs (NASDAQ:CBLI) opened at 3.72 on Monday. Cleveland BioLabs has a one year low of $1.22 and a one year high of $5.55. The company’s market cap is $41.96 million. The stock’s 50 day moving average price is $3.31 and its 200 day moving average price is $2.06.
Cleveland BioLabs (NASDAQ:CBLI) last announced its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.15) earnings per share for the quarter. The company had revenue of $0.58 million during the quarter. Cleveland BioLabs had a negative net margin of 75.04% and a negative return on equity of 21.29%. Equities analysts predict that Cleveland BioLabs will post ($0.16) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/05/29/short-interest-in-cleveland-biolabs-inc-cbli-drops-by-30-7.html.
Cleveland BioLabs Company Profile
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.